Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Therapy induced hypermutation to stimulate immune responses in recurrent cancer
FY 2018-19
Summary
In the battle against cancer, massive amounts of time and resources have gone towards the development of chemotherapeutic agents that act to kill cancer cells, while leaving healthy cells relatively unaffected. Unfortunately, when these drugs are unable to fully eradicate all cancer populations, recurrence can occur which leads to prolonged treatment, increased costs, and further stress on the patient. Due to this risk, it is vital that initial treatment plans take into account the widely varying characteristics of each cancer and give the best chance for complete remission. One way this can be accomplished is through the process of "synthetic hypermutation", which is a gene-drug interaction that gives rise to an unexpected number of mutations in surviving cells.
When hypermutation occurs naturally, it is often indicative of positive clinical outcomes due to the increased response of the host's immune system against the cancer cells. The elevated immune response is due to the presence of neoantigens, which are mutated proteins found in tumour cells but not in normal cells. Considering this, the Stirling Lab (BC Cancer Research Centre) hypothesizes that cells can be hypermutated in response to certain genotoxic chemotherapies, creating more of these neoantigens and thereby stimulating the host immune response. My research will involve screening a multitude of drugs and chemicals to determine which will result in the highest mutation rate and consistent generation of mutant proteins in these cells. Ideally, these results will allow clinicians to make informed decisions when deciding between chemotherapies and ultimately lead to improved treatment outcomes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
415354
Name
White Justin M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Therapy induced hypermutation to stimulate immune responses in recurrent cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Chemotherapy; Genetics; Hypermutation; Immune Response; P53; Personalized Medicine; Sequencing
Abstract
In the battle against cancer, massive amounts of time and resources have gone towards the development of chemotherapeutic agents that act to kill cancer cells, while leaving healthy cells relatively unaffected. Unfortunately, when these drugs are unable to fully eradicate all cancer populations, recurrence can occur which leads to prolonged treatment, increased costs, and further stress on the patient. Due to this risk, it is vital that initial treatment plans take into account the widely varying characteristics of each cancer and give the best chance for complete remission. One way this can be accomplished is through the process of "synthetic hypermutation", which is a gene-drug interaction that gives rise to an unexpected number of mutations in surviving cells.
When hypermutation occurs naturally, it is often indicative of positive clinical outcomes due to the increased response of the host's immune system against the cancer cells. The elevated immune response is due to the presence of neoantigens, which are mutated proteins found in tumour cells but not in normal cells. Considering this, the Stirling Lab (BC Cancer Research Centre) hypothesizes that cells can be hypermutated in response to certain genotoxic chemotherapies, creating more of these neoantigens and thereby stimulating the host immune response. My research will involve screening a multitude of drugs and chemicals to determine which will result in the highest mutation rate and consistent generation of mutant proteins in these cells. Ideally, these results will allow clinicians to make informed decisions when deciding between chemotherapies and ultimately lead to improved treatment outcomes.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
White, Justin M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~